Literature DB >> 15995046

Effectiveness of the 2003-2004 influenza vaccine among children 6 months to 8 years of age, with 1 vs 2 doses.

Debra P Ritzwoller1, Carolyn Buxton Bridges, Susan Shetterly, Kristi Yamasaki, Margarette Kolczak, Eric K France.   

Abstract

OBJECTIVE: To evaluate the effectiveness of 1 and 2 doses of the 2003-2004 influenza vaccine in preventing medically attended influenza-like illness (ILI) among children 6 to 23 months and 6 months to 8 years of age. DESIGN AND METHODS: Outpatient and emergency department visits and immunization records were used to conduct a retrospective cohort study among children 6 months to 8 years of age. ILI and pneumonia and influenza (P&I) outcomes were defined on the basis of International Classification of Diseases, Ninth Revision, codes. Influenza vaccine effectiveness (VE) was calculated as (1 - hazard rate ratio) x 100.
RESULTS: A total of 29726 children were included in the analyses; 17.3% were 6 to 23 months of age. By November 19, 2003, the start of peak influenza activity, 7.5% and 9.9% of children 6 months to 8 years were fully or partially vaccinated against influenza, respectively. For fully vaccinated children 6 to 23 months of age, VE against ILI and P&I was 25% and 49%, respectively. No statistically significant reduction in ILI or P&I rates was observed for partially vaccinated children 6 to 23 months of age (-3% and 22%, respectively). For fully vaccinated children 6 months to 8 years of age, VE against ILI and P&I was 23% and 51%, respectively. For partial vaccination, VE was significant only for P&I (23%).
CONCLUSIONS: Despite a suboptimal match between the influenza vaccine and predominant circulating strains, influenza vaccination provided substantial protection for fully vaccinated children and possibly some protection for partially vaccinated children <9 years of age. These findings support vaccinating targeted children even when the vaccine match is suboptimal, and they highlight the need to vaccinate previously unvaccinated children with 2 doses for optimal protection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15995046     DOI: 10.1542/peds.2005-0049

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  56 in total

1.  Suppression of influenza A virus replication in human lung epithelial cells by noncytotoxic concentrations bafilomycin A1.

Authors:  Behzad Yeganeh; Saeid Ghavami; Andrea L Kroeker; Thomas H Mahood; Gerald L Stelmack; Thomas Klonisch; Kevin M Coombs; Andrew J Halayko
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-10-31       Impact factor: 5.464

2.  Release of the statement on influenza for the 2007 2008 season from the National Advisory Committee on Immunization.

Authors:  Joanne M Langley
Journal:  CMAJ       Date:  2007-10-23       Impact factor: 8.262

3.  Effectiveness of seasonal inactivated influenza vaccination in Japanese schoolchildren: an epidemiologic study at the community level.

Authors:  Yasutaka Kuniyoshi; Taku Obara; Mami Ishikuro; Hiroko Matsubara; Masato Nagai; Keiko Murakami; Aoi Noda; Masahiro Kikuya; Shigeo Kure; Shinichi Kuriyama
Journal:  Hum Vaccin Immunother       Date:  2019-09-20       Impact factor: 3.452

4.  Annual vaccination against influenza virus hampers development of virus-specific CD8⁺ T cell immunity in children.

Authors:  Rogier Bodewes; Pieter L A Fraaij; Martina M Geelhoed-Mieras; Carel A van Baalen; Harm A W M Tiddens; Annemarie M C van Rossum; Fiona R van der Klis; Ron A M Fouchier; Albert D M E Osterhaus; Guus F Rimmelzwaan
Journal:  J Virol       Date:  2011-08-31       Impact factor: 5.103

5.  Complete Influenza Vaccination Trends for Children Six to Twenty-Three Months.

Authors:  Tammy A Santibanez; Lisa A Grohskopf; Yusheng Zhai; Katherine E Kahn
Journal:  Pediatrics       Date:  2016-02-02       Impact factor: 7.124

6.  Mitigation strategies for pandemic influenza in the United States.

Authors:  Timothy C Germann; Kai Kadau; Ira M Longini; Catherine A Macken
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-03       Impact factor: 11.205

7.  Influenza-associated cystic fibrosis pulmonary exacerbations.

Authors:  Justin R Ortiz; Kathleen M Neuzil; John C Victor; Anna Wald; Moira L Aitken; Christopher H Goss
Journal:  Chest       Date:  2009-12-04       Impact factor: 9.410

8.  Signs of the 2009 influenza pandemic in the New York-Presbyterian Hospital electronic health records.

Authors:  Hossein Khiabanian; Antony B Holmes; Brendan J Kelly; Mrinalini Gururaj; George Hripcsak; Raul Rabadan
Journal:  PLoS One       Date:  2010-09-09       Impact factor: 3.240

Review 9.  Influenza: the virus and prophylaxis with inactivated influenza vaccine in "at risk" groups, including COPD patients.

Authors:  Arnt-Ove Hovden; Rebecca Jane Cox; Lars Reinhardt Haaheim
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007

10.  Vaccination against human influenza A/H3N2 virus prevents the induction of heterosubtypic immunity against lethal infection with avian influenza A/H5N1 virus.

Authors:  Rogier Bodewes; Joost H C M Kreijtz; Chantal Baas; Martina M Geelhoed-Mieras; Gerrie de Mutsert; Geert van Amerongen; Judith M A van den Brand; Ron A M Fouchier; Albert D M E Osterhaus; Guus F Rimmelzwaan
Journal:  PLoS One       Date:  2009-05-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.